Discovery of Python Molecule Offers New Hope for Obesity Treatments

Recent research has identified a molecule from Burmese pythons that could lead to a new class of obesity drugs. This molecule, known as pTOS, significantly influences metabolism and appetite regulation. When administered to obese mice, pTOS resulted in reduced food intake and a weight loss of approximately 9% over 28 days. The study, conducted by scientists at Stanford University and the University of Colorado Boulder, highlights the potential of leveraging unique animal adaptations to address human metabolic disorders.

The Guardian

Pythons exhibit remarkable metabolic capabilities, consuming prey that can weigh up to their own body weight and then fasting for extended periods. The research initially aimed to explore the metabolites responsible for the pythons' rapid heart growth post-feeding. In their investigation, scientists discovered over 200 molecules that surged in the snakes' blood after meals, with pTOS increasing more than 1,000-fold. Unlike existing GLP-1 medications, such as Wegovy, which slow stomach emptying and can cause side effects like nausea, pTOS appears to target the hypothalamus—a brain region that regulates appetite—without these adverse effects.

The Guardian

The findings suggest that pTOS could serve as a natural appetite suppressant, offering a promising alternative to current obesity treatments. Professor Leslie Leinwand, a co-author of the study, emphasized the significance of this discovery, stating, “We’ve basically discovered an appetite suppressant that works in mice without some of the side effects that GLP-1 drugs have.” Given that pTOS is naturally present in human urine, its safety profile appears favorable for future clinical applications.

The Guardian

Despite the promising results, experts caution that further research is necessary before pTOS can be considered for human use. Concerns remain regarding the translation of findings from mice to humans, as metabolic responses can vary significantly across species. Additionally, the long-term effects of pTOS administration in humans are yet to be understood.

The Guardian

Dr. Jonathan Long, an associate professor at Stanford University and co-author of the research, remarked on the broader implications of studying such unique animals: “But maybe by studying these animals, we can identify molecules or metabolic pathways that also affect human metabolism.” The research findings were published in the journal *Nature Metabolism*, marking a significant step forward in obesity research.

The Guardian

Future studies will focus on the clinical applications of pTOS, including its potential effects on human metabolism and appetite regulation. Researchers aim to explore the safety and efficacy of pTOS in human trials, which could pave the way for innovative obesity treatments that minimize side effects associated with current medications.

The Guardian